잠시만 기다려 주세요. 로딩중입니다.

Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer

Korean Journal of Internal Medicine 2020년 35권 6호 p.1489 ~ 1496
원혜성, 김용석, 김정수, 장은덕, 나세정, 황인영, 이동수,
소속 상세정보
원혜성 ( Won Hye-Sung ) - Catholic University College of Medicine Uijeongbu St. Mary’s Hospital Department of Internal Medicine
김용석 ( Kim Yong-Seok ) - Catholic University College of Medicine Uijeongbu St. Mary’s Hospital Department of Surgery
김정수 ( Kim Jeong-Soo ) - Catholic University College of Medicine Uijeongbu St. Mary’s Hospital Department of Surgery
장은덕 ( Chang Eun-Deok ) - Catholic University College of Medicine Uijeongbu St. Mary’s Hospital Department of Hospital Pathology
나세정 ( Na Sae-Jung ) - Catholic University College of Medicine Uijeongbu St. Mary’s Hospital Department of Nuclear Medicine
황인영 ( Whang In-Yong ) - Catholic University College of Medicine Uijeongbu St. Mary’s Hospital Department of Radiology
이동수 ( Lee Dong-Soo ) - Catholic University College of Medicine Uijeongbu St. Mary’s Hospital Department of Radiation Oncology

Abstract


Background/Aims: We evaluated the efficacy of docetaxel and epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer and assessed the predictive factors for response to neoadjuvant chemotherapy and prognostic factors related to relapse-free survival.

Methods: Forty patients who received docetaxel and epirubicinas neoadjuvant chemotherapy for locally advanced breast cancer were evaluated retrospectively. Neoadjuvant chemotherapy consisted of intravenous injection of 75 mg/m2 docetaxel and 60 mg/m2 epirubucin on day 1, every 21 days, and two to six cycles.

Results: Twenty-five (62.5%) patients showed a partial response, and 15 (37.5%) patients showed a stable disease in the first response evaluation after two or three cycles of neoadjuvant chemotherapy. In the second response evaluation of nine patients who received six cycles of neoadjuvant chemotherapy, one patient achieved a complete response, but two patients with hormone receptor-negative, human epidermal growth factor receptor 2-positive breast cancer experienced disease progression. Twenty-five (62.5%) patients experienced downstaging after neoadjuvant chemotherapy. Patients with > 20% pretreatment Ki-67 and decrease of Ki-67 between pre- and post-neoadjuvant chemotherapy showed a trend for better response. In multivariate analysis, advanced pathological stage showed a significant negative effect on relapse-free survival.

Conclusions: Docetaxel and epirubicin neoadjuvant chemotherapy showed a good response in locally advanced breast cancer. Pretreatment Ki-67 and change of Ki-67 may play a role as predictive factor for response to neoadjuvant chemotherapy.

키워드

Breast neoplasms; Chemotherapy; Docetaxel; Epirubicin; Ki-67

원문 및 링크아웃 정보

 

등재저널 정보